Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review
- PMID: 15769640
- DOI: 10.2741/1634
Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review
Abstract
The acquisition of multi-drug resistance (MDR) in cancer cells subjected to anticancer agents remains a formidable obstacle to successful therapeutic outcomes in cancer patients. As the name implies, the resistance phenotype (MDR) is not typically limited to the drug initially used to eradicate cancer but is often transferred to structurally unrelated chemotherapeutic agents. The mechanisms underlying the development of MDR have been extensively studied and are considered multifactorial. Interestingly, recent observations have shown that altered intracellular distribution of drugs may play an important role in the establishment of the MDR phenotype. Such intracellular redistribution events may reduce the opportunity for a drug molecule to permeate into a drug _target-containing compartment and thus limit its therapeutic effect. This review summarizes cases in which intracellular redistribution of drugs has been associated with the emergence of MDR in cancer cells. The review also provides a general overview regarding intracellular compartmentalization mechanisms of drugs in cells, which will include some of the known factors/conditions that influence the accumulation of drugs into specific cellular compartments. Finally, potential strategies for overcoming this resistance phenotype are discussed.
Similar articles
-
New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer.Curr Pharm Des. 2015;21(38):5589-604. doi: 10.2174/1381612821666151002113546. Curr Pharm Des. 2015. PMID: 26429711 Review.
-
The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia.Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110. doi: 10.5414/cpp38094. Int J Clin Pharmacol Ther. 2000. PMID: 10739113 Review.
-
Molecular mechanisms of multidrug resistance in cancer chemotherapy.Pathol Res Pract. 1996 Jul;192(7):768-80. doi: 10.1016/S0344-0338(96)80099-9. Pathol Res Pract. 1996. PMID: 8880878 Review.
-
Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.World J Gastroenterol. 2002 Aug;8(4):644-9. doi: 10.3748/wjg.v8.i4.644. World J Gastroenterol. 2002. PMID: 12174371 Free PMC article.
-
Multidrug resistance: can different keys open the same lock?Drug Resist Updat. 2002 Apr;5(2):61-4. doi: 10.1016/s1368-7646(02)00020-1. Drug Resist Updat. 2002. PMID: 12135581 Review.
Cited by
-
RBC-derived vesicles as a systemic delivery system of doxorubicin for lysosomal-mitochondrial axis-improved cancer therapy.J Adv Res. 2020 Nov 24;30:185-196. doi: 10.1016/j.jare.2020.11.009. eCollection 2021 May. J Adv Res. 2020. PMID: 34026295 Free PMC article.
-
Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma.Cell Death Dis. 2019 Oct 3;10(10):749. doi: 10.1038/s41419-019-1989-z. Cell Death Dis. 2019. PMID: 31582741 Free PMC article.
-
Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance.Sci Rep. 2018 Jul 3;8(1):10039. doi: 10.1038/s41598-018-28265-5. Sci Rep. 2018. PMID: 29968769 Free PMC article.
-
_targeting the oncogenic Met receptor by antibodies and gene therapy.Oncogene. 2015 Apr 9;34(15):1883-9. doi: 10.1038/onc.2014.142. Epub 2014 Jun 2. Oncogene. 2015. PMID: 24882574 Review.
-
Photoacoustic "nanobombs" fight against undesirable vesicular compartmentalization of anticancer drugs.Sci Rep. 2015 Oct 20;5:15527. doi: 10.1038/srep15527. Sci Rep. 2015. PMID: 26483341 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials